Review Article
Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer
Table 2
Trials using Anti-EGFR mABs as monotherapy for chemoresistant mCRC selected by KRAS status.
| Trial (author) | Phase |
KRAS |
Protocol |
Number enrolled | Results
|
HR (95% CI) | value | PFS | OS |
| — (Amado et al.) [14] |
III | WT | Panitumumab BSC | 124 119 | 12.3 wks. 7.3 wks. | 8.1 mos. 7.6 mos. | PFS: 0.45 (0.34–0.59) OS: 0.99 (0.75–1.29) | <0.001 NR | MUT | Panitumumab BSC | 84 100 | 7.4 wks. 7.3 wks. | 4.9 mos. 4.4 mos. | PFS: 0.99 (0.73–1.36) OS: 1.02 (0.75–1.39) | NR NR |
|
|
BSC: best supportive care, WT: wild type, MUT: mutated, and NR: not reported.
|